A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Sponsor
Taisho Pharmaceutical Co., Ltd.
Study ID
NCT07285304
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Hyperphosphatemia Patients on Hemodialysis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TS-172 — DRUG
    oral administration of TS-172 20\~60 mg/day

Study Details

A clinical study to evaluate the long-term safety and efficacy of TS-172 in hyperphosphatemia patients on hemodialysis.

Key Dates

Start date
Dec 1, 2025
Status verified
Dec 2025
Primary completion
Jul 31, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
300 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TS-172

Primary Outcome Measure

Incidence of adverse events [ Time Frame: Up to 26 weeks or up to 52 weeks ]

Central Contacts